

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Nanjing Jinsirui Biotechnology Co., Ltd. (“**Nanjing Jinsirui**”), its indirect wholly-owned subsidiary has recently entered into a non-binding cooperative memorandum of understanding (the “**MOU**”) with Innovation Center for Immune Therapy of Tsinghua University (“**ICIT**”), to commence in-depth cooperation in respect of discovery and development of biologics to assist the transformation of high potential scientific research to biologics with high clinical value. Through the cooperation, both parties will combine the advantages of scientific research and the talent pool in immunology in Tsinghua University, with the Company’s technology platform for discovery and development of biologics to accelerate the R&D and industrialization of innovative biologics.

INFORMATION ON ICIT

ICIT was jointly founded by the Institutes for Immunology and Institute of Technology Transfer at Tsinghua University in August 2016. ICIT aims to promote an innovative technology incubation model, and, on the basis of original research of immunology as well as through establishment of strategic cooperation with internationally renowned pharmaceutical companies, cultivates transformation of research results into biologics to accelerate the transformation of scientific research in immunology to clinical application.

INFORMATION ON THE GROUP AND NANJING JINSIRUI

The Group is principally engaged in the provision of (i) bio-science services and products, (ii) industrial synthetic biology products, and (iii) precision immune-cell therapy.

Nanjing Jinsirui is a limited liability company incorporated in the People's Republic of China and is an indirect wholly-owned subsidiary of the Company.

Please note that the MOU was entered into to record the preliminary mutual understanding between the parties and does not involve any specific rights or obligations. No party shall be liable for the breach of the MOU. Further document(s) or agreement(s) shall be entered into between the parties if there is any subsequent cooperation. Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate to deal in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 18 June 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*